ABPO (Abpro Holdings) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


ABPO Abpro Holdings Inc ABPO
9 GF Score
Price $0.22
! 1 Warning Sign
View Full Analysis

What is Abpro Holdings ROE % Adjusted to Book Value?

Abpro Holdings ABPO +3.66% 9 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates ABPO with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

Abpro Holdings's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Abpro Holdings's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Abpro Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Abpro Holdings ROE % Adjusted to Book Value Related Terms

Abpro Holdings ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Abpro Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abpro Holdings ROE % Adjusted to Book Value Chart

Abpro Holdings Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00

Abpro Holdings Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 Negative Equity 0.00

ABPO vs LYRA, ATXI, PTIX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Abpro Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abpro Holdings ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abpro Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Abpro Holdings's ROE % Adjusted to Book Value falls into.


ABPO
9GF Score
Abpro Holdings Inc ABPO
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abpro Holdings ROE % Adjusted to Book Value Calculation

Abpro Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Abpro Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Abpro Holdings (ABPO) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Abpro Holdings and its competitors.
Is Abpro Holdings' ROE % Adjusted to Book Value too high?
Abpro Holdings' current ROE % Adjusted to Book Value is 0.00%. Overall, Abpro Holdings has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Abpro Holdings' ROE % Adjusted to Book Value compare to LYRA and ATXI?
Abpro Holdings' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Abpro Holdings and its competitors. Abpro Holdings's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abpro Holdings stock overvalued right now?
Abpro Holdings (ABPO) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Abpro Holdings' overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Abpro Holdings (ABPO), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abpro Holdings Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. The company is focused on novel antibody constructs for immuno-oncology, ophthalmology, and infectious diseases. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, the company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
9GF Score

Get the complete analysis for ABPO

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price